{"product_id":"fundamentals-of-pharmacology-for-paramedics-isbn-9781119724285","title":"Fundamentals of Pharmacology for Paramedics","description":"\u003cp\u003e\u003ci\u003eFundamentals of Pharmacology for Paramedics\u003c\/i\u003e provides students with the insight and understanding of pharmacological essentials needed to respond effectively to the patients' needs. This textbook will help students improve, expand, and enhance their expertise and the overall health and wellbeing of their patients, while boosting their self-confidence as paramedics in the process. This textbook integrates the extensive knowledge of pharmacology into a workable and accessible plan of care that will help to improve patient care. The book also includes:\u003c\/p\u003e \u003cul\u003e \u003cli\u003eThorough introductions to pharmacology and how to use pharmaceutical, and prescribing reference guides\u003c\/li\u003e \u003cli\u003eComprehensive explorations of the legal and ethical issues of pharmacology within paramedicine and the role of the paramedic in medicines management\u003c\/li\u003e \u003cli\u003ePractical discussions of pharmacodynamics, pharmacokinetics, drug formulations, and adverse drug reactions\u003c\/li\u003e \u003cli\u003eIn-depth examinations of a wide variety of medicines, including analgesics, antibacterials, and medications used in the cardiovascular, renal, respiratory, gastrointestinal, and nervous systems\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eWritten for students of paramedicine, \u003ci\u003eFundamentals of Pharmacology for Paramedics\u003c\/i\u003e would also prove an indispensable resource for practicing paramedics seeking a practical, one-stop reference on a challenging subject.\u003c\/p\u003e \u003cp\u003eContributors xiii\u003c\/p\u003e \u003cp\u003ePreface xxi\u003c\/p\u003e \u003cp\u003eAcknowledgements xxiii\u003c\/p\u003e \u003cp\u003ePrefixes, suffixes and abbreviations xxiv\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 1: Introduction to pharmacology 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eSuzanne Evans and Tanya Somani\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAim 1\u003c\/p\u003e \u003cp\u003eNaming and classifying drugs 5\u003c\/p\u003e \u003cp\u003eHow drugs bring about their actions 6\u003c\/p\u003e \u003cp\u003eHow are we able to manipulate physiological function using drugs? 6\u003c\/p\u003e \u003cp\u003eReceptors as sites of drug action 7\u003c\/p\u003e \u003cp\u003eEnzymes as sites of drug action 7\u003c\/p\u003e \u003cp\u003eIon channels 7\u003c\/p\u003e \u003cp\u003eTransport molecules 9\u003c\/p\u003e \u003cp\u003eSelectivity of binding and its effect 11\u003c\/p\u003e \u003cp\u003eThe drug–body interaction is a dynamic process 11\u003c\/p\u003e \u003cp\u003eConclusion 14\u003c\/p\u003e \u003cp\u003eGlossary 14\u003c\/p\u003e \u003cp\u003eReferences 15\u003c\/p\u003e \u003cp\u003eFurther reading 15\u003c\/p\u003e \u003cp\u003eMultiple-choice questions 15\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 2: How to use pharmaceutical and prescribing reference guides 18\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eNigel Conway and Jennifer Dod\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAim 18\u003c\/p\u003e \u003cp\u003eIntroduction 19\u003c\/p\u003e \u003cp\u003eHCPC Standards of conduct, performance and ethics 19\u003c\/p\u003e \u003cp\u003eHCPC Standards of proficiency for paramedics 20\u003c\/p\u003e \u003cp\u003eJoint Royal Colleges Ambulance Liaison Committee (JRCALC) Clinical Practice Guidelines 21\u003c\/p\u003e \u003cp\u003eJRCALC Update information 22\u003c\/p\u003e \u003cp\u003eHow to navigate the JRCALC Guidelines 23\u003c\/p\u003e \u003cp\u003eJRCALC Pocket Book 30\u003c\/p\u003e \u003cp\u003eJRCALC Guidelines digital application (app) 31\u003c\/p\u003e \u003cp\u003eUseful additional resources 32\u003c\/p\u003e \u003cp\u003eBritish National Formulary (BNF) 32\u003c\/p\u003e \u003cp\u003eMonthly Index of Medical Specialities 33\u003c\/p\u003e \u003cp\u003eElectronic Medicines Compendium (EMC) 34\u003c\/p\u003e \u003cp\u003eConclusion 34\u003c\/p\u003e \u003cp\u003eDisclaimer 35\u003c\/p\u003e \u003cp\u003eReferences 35\u003c\/p\u003e \u003cp\u003eFurther reading 35\u003c\/p\u003e \u003cp\u003eMultiple-choice questions 35\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 3: Legal and ethical issues 37\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eClaire Leader, Emma Senior, Deborah Flynn and Paul Younger\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAim 37\u003c\/p\u003e \u003cp\u003eIntroduction 38\u003c\/p\u003e \u003cp\u003eThe law 38\u003c\/p\u003e \u003cp\u003eEthical principles and theories 39\u003c\/p\u003e \u003cp\u003eRegulatory bodies 43\u003c\/p\u003e \u003cp\u003eResearch 45\u003c\/p\u003e \u003cp\u003eConclusion 47\u003c\/p\u003e \u003cp\u003eGlossary 47\u003c\/p\u003e \u003cp\u003eReferences 48\u003c\/p\u003e \u003cp\u003eFurther reading 49\u003c\/p\u003e \u003cp\u003eMultiple-choice questions 50\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 4: Medicines management and the role of the paramedic 52\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eAnnette Hand, Carol Wills and Paul Younger\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAim 52\u003c\/p\u003e \u003cp\u003eIntroduction 53\u003c\/p\u003e \u003cp\u003eMedicines management 53\u003c\/p\u003e \u003cp\u003eManufacturing, marketing, procurement and sale 54\u003c\/p\u003e \u003cp\u003eSelection 55\u003c\/p\u003e \u003cp\u003eSupply 55\u003c\/p\u003e \u003cp\u003ePatient-specific directions 56\u003c\/p\u003e \u003cp\u003ePrescriptions 56\u003c\/p\u003e \u003cp\u003ePatient Group Directions 56\u003c\/p\u003e \u003cp\u003eExemptions 57\u003c\/p\u003e \u003cp\u003ePrescribing 59\u003c\/p\u003e \u003cp\u003eHandling and administration 60\u003c\/p\u003e \u003cp\u003eSpecial consideration: Controlled Drugs and critical medications 62\u003c\/p\u003e \u003cp\u003eGroups requiring special considerations 63\u003c\/p\u003e \u003cp\u003eMonitoring for side-effects 64\u003c\/p\u003e \u003cp\u003eMedicines optimisation 64\u003c\/p\u003e \u003cp\u003eSafety in medicines management 65\u003c\/p\u003e \u003cp\u003eStorage and disposal 66\u003c\/p\u003e \u003cp\u003eConclusion 66\u003c\/p\u003e \u003cp\u003eReferences 66\u003c\/p\u003e \u003cp\u003eFurther reading 68\u003c\/p\u003e \u003cp\u003eMultiple-choice questions 68\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 5: Pharmacodynamics and pharmacokinetics 70\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eDan Davern\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAim 70\u003c\/p\u003e \u003cp\u003eIntroduction 70\u003c\/p\u003e \u003cp\u003eProfessional regulatory council 71\u003c\/p\u003e \u003cp\u003eProgrammes of education and training 71\u003c\/p\u003e \u003cp\u003ePharmacokinetics 71\u003c\/p\u003e \u003cp\u003eThe pharmacokinetic processes 71\u003c\/p\u003e \u003cp\u003ePhase 1: absorption 72\u003c\/p\u003e \u003cp\u003ePhase 2: distribution 76\u003c\/p\u003e \u003cp\u003ePhase 3: metabolism (biotransformation) 77\u003c\/p\u003e \u003cp\u003ePhase 4: elimination 79\u003c\/p\u003e \u003cp\u003ePharmacodynamics 81\u003c\/p\u003e \u003cp\u003eAgonists and antagonists 82\u003c\/p\u003e \u003cp\u003eDrug potency and efficacy 84\u003c\/p\u003e \u003cp\u003eTherapeutic index 84\u003c\/p\u003e \u003cp\u003eAdverse drug reactions 85\u003c\/p\u003e \u003cp\u003eConclusion 87\u003c\/p\u003e \u003cp\u003eReferences 87\u003c\/p\u003e \u003cp\u003eFurther reading 87\u003c\/p\u003e \u003cp\u003eMultiple-choice questions 88\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 6: Drug formulations 90\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eSarah Dineen-Griffin and Barbara C. Wimmer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAim 90\u003c\/p\u003e \u003cp\u003eIntroduction 91\u003c\/p\u003e \u003cp\u003eRoutes of drug administration 91\u003c\/p\u003e \u003cp\u003eParenteral administration 92\u003c\/p\u003e \u003cp\u003eIntravenous administration 92\u003c\/p\u003e \u003cp\u003eSubcutaneous administration 93\u003c\/p\u003e \u003cp\u003eIntramuscular administration 93\u003c\/p\u003e \u003cp\u003eIntraosseous administration 95\u003c\/p\u003e \u003cp\u003eIntrathecal administration 95\u003c\/p\u003e \u003cp\u003eIntradermal administration 95\u003c\/p\u003e \u003cp\u003eFormulations 97\u003c\/p\u003e \u003cp\u003eLocalised versus long-acting injectable formulations 97\u003c\/p\u003e \u003cp\u003eTopical formulations 97\u003c\/p\u003e \u003cp\u003eInhaled formulations 99\u003c\/p\u003e \u003cp\u003eEnteral formulations 101\u003c\/p\u003e \u003cp\u003eRectal formulations 105\u003c\/p\u003e \u003cp\u003eConclusion 105\u003c\/p\u003e \u003cp\u003eGlossary 106\u003c\/p\u003e \u003cp\u003eReferences 106\u003c\/p\u003e \u003cp\u003eFurther reading 108\u003c\/p\u003e \u003cp\u003eMultiple-choice questions 108\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 7: Adverse drug reactions 110\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eMatt Dixon\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAim 110\u003c\/p\u003e \u003cp\u003eWhat is an adverse drug reaction? 110\u003c\/p\u003e \u003cp\u003eClassification of adverse drug reactions 111\u003c\/p\u003e \u003cp\u003eHow prevalent are adverse drug reactions? 111\u003c\/p\u003e \u003cp\u003eWho is more likely to experience adverse drug reactions? 112\u003c\/p\u003e \u003cp\u003eRecognising signs and symptoms of adverse drug reactions 114\u003c\/p\u003e \u003cp\u003eAnaphylaxis 114\u003c\/p\u003e \u003cp\u003eRashes and skin eruptions 115\u003c\/p\u003e \u003cp\u003eSerum sickness 115\u003c\/p\u003e \u003cp\u003eRenal disorders 115\u003c\/p\u003e \u003cp\u003eGeriatric syndrome 116\u003c\/p\u003e \u003cp\u003eIdiosyncratic reactions 117\u003c\/p\u003e \u003cp\u003ePreventing adverse drug reactions 117\u003c\/p\u003e \u003cp\u003eManaging adverse drug reactions 117\u003c\/p\u003e \u003cp\u003eReporting adverse drug reactions 119\u003c\/p\u003e \u003cp\u003eConclusion 122\u003c\/p\u003e \u003cp\u003eReferences 122\u003c\/p\u003e \u003cp\u003eFurther reading 123\u003c\/p\u003e \u003cp\u003eMultiple-choice questions 123\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 8: Analgesics 125\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eTom Mallinson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAim 125\u003c\/p\u003e \u003cp\u003ePain and analgesia 125\u003c\/p\u003e \u003cp\u003eUnderstanding and assessing pain 125\u003c\/p\u003e \u003cp\u003eWhy do we treat pain? 126\u003c\/p\u003e \u003cp\u003ePsychology of pain 126\u003c\/p\u003e \u003cp\u003ePhysiology of pain 127\u003c\/p\u003e \u003cp\u003ePain transmission 127\u003c\/p\u003e \u003cp\u003ePain modulation 128\u003c\/p\u003e \u003cp\u003eTypes of pain 129\u003c\/p\u003e \u003cp\u003eAssessment of pain 131\u003c\/p\u003e \u003cp\u003eApproach to analgesia 132\u003c\/p\u003e \u003cp\u003eParacetamol 133\u003c\/p\u003e \u003cp\u003eNon-steroidal anti-inflammatory drugs 133\u003c\/p\u003e \u003cp\u003eInhalational analgesia 136\u003c\/p\u003e \u003cp\u003eOpioids 137\u003c\/p\u003e \u003cp\u003eAntagonists 141\u003c\/p\u003e \u003cp\u003eAtypical analgesics 142\u003c\/p\u003e \u003cp\u003eAntidepressants and antiepileptics 143\u003c\/p\u003e \u003cp\u003eAdjuncts to analgesia 143\u003c\/p\u003e \u003cp\u003eMagnesium sulfate 143\u003c\/p\u003e \u003cp\u003eLocal anaesthetics 143\u003c\/p\u003e \u003cp\u003eConclusion 144\u003c\/p\u003e \u003cp\u003eGlossary 145\u003c\/p\u003e \u003cp\u003eReferences 146\u003c\/p\u003e \u003cp\u003eFurther reading 147\u003c\/p\u003e \u003cp\u003eMultiple-choice questions 147\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 9: Antibacterials 149\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eDean Whiting, Deborah Flynn and Dawn Ball\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAim 149\u003c\/p\u003e \u003cp\u003eIntroduction 149\u003c\/p\u003e \u003cp\u003eLanguage and terminology 150\u003c\/p\u003e \u003cp\u003eAntibacterial mechanisms of action 150\u003c\/p\u003e \u003cp\u003eDisruption of bacterial cell wall synthesis: beta-lactams 151\u003c\/p\u003e \u003cp\u003eInterference in folate metabolism: sulfonamides, trimethoprim 151\u003c\/p\u003e \u003cp\u003eInhibition of bacterial DNA synthesis: quinolones 151\u003c\/p\u003e \u003cp\u003eInhibition of bacterial protein synthesis: tetracyclines, aminoglycosides, macrolides, chloramphenicol, lincosamides 151\u003c\/p\u003e \u003cp\u003eChoosing the right treatment 151\u003c\/p\u003e \u003cp\u003eAntimicrobial resistance 151\u003c\/p\u003e \u003cp\u003ePreventing antimicrobial resistance 152\u003c\/p\u003e \u003cp\u003eAntimicrobial stewardship (AMS) 153\u003c\/p\u003e \u003cp\u003eAntibacterials by clinical use 153\u003c\/p\u003e \u003cp\u003eBeta-lactams 153\u003c\/p\u003e \u003cp\u003eTetracyclines 157\u003c\/p\u003e \u003cp\u003eChloramphenicol 158\u003c\/p\u003e \u003cp\u003eWhen administered in combination with phenytoin, monitor seizure pattern. Aminoglycosides 159\u003c\/p\u003e \u003cp\u003eMacrolides 161\u003c\/p\u003e \u003cp\u003eLincosamides 162\u003c\/p\u003e \u003cp\u003eConclusion 163\u003c\/p\u003e \u003cp\u003eReferences 163\u003c\/p\u003e \u003cp\u003eFurther reading 164\u003c\/p\u003e \u003cp\u003eMultiple-choice questions 164\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 10: Medications used in the cardiovascular system 167\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eLisa Clegg and Fraser Russell\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAim 167\u003c\/p\u003e \u003cp\u003eCardiovascular diseases 167\u003c\/p\u003e \u003cp\u003eHypertension and heart failure 168\u003c\/p\u003e \u003cp\u003eManagement of hypertension and heart failure 168\u003c\/p\u003e \u003cp\u003eAcute coronary Syndrome (ACS) 173\u003c\/p\u003e \u003cp\u003eManagement of acute coronary syndrome 173\u003c\/p\u003e \u003cp\u003eConclusion 177\u003c\/p\u003e \u003cp\u003eGlossary 177\u003c\/p\u003e \u003cp\u003eReferences 178\u003c\/p\u003e \u003cp\u003eFurther reading 179\u003c\/p\u003e \u003cp\u003eMultiple-choice questions 180\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 11: Medications used in the renal system 182\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eAnthony Kitchener\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAim 182\u003c\/p\u003e \u003cp\u003eIntroduction 183\u003c\/p\u003e \u003cp\u003eAcute kidney injury 183\u003c\/p\u003e \u003cp\u003eChronic kidney disease 185\u003c\/p\u003e \u003cp\u003eManagement of CKD 185\u003c\/p\u003e \u003cp\u003eElectrolyte abnormalities resulting from poor renal function 187\u003c\/p\u003e \u003cp\u003eHyponatraemia (low serum sodium) 187\u003c\/p\u003e \u003cp\u003eHypokalaemia (low serum potassium) and hyperkalaemia (high serum potassium) 187\u003c\/p\u003e \u003cp\u003eUrinary retention and incontinence 187\u003c\/p\u003e \u003cp\u003eDrug-induced renal damage 188\u003c\/p\u003e \u003cp\u003eDrugs that act on the renal system 188\u003c\/p\u003e \u003cp\u003eDiuretics 188\u003c\/p\u003e \u003cp\u003eDrugs used to treat urinary retention and urinary incontinence 193\u003c\/p\u003e \u003cp\u003eConclusion 195\u003c\/p\u003e \u003cp\u003eGlossary 198\u003c\/p\u003e \u003cp\u003eReferences 200\u003c\/p\u003e \u003cp\u003eFurther reading 201\u003c\/p\u003e \u003cp\u003eMultiple-choice questions 201\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 12: Medications and diabetes mellitus 203\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eHayley Croft and Olivia Thornton\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAim 203\u003c\/p\u003e \u003cp\u003eIntroduction 204\u003c\/p\u003e \u003cp\u003eHormonal control of blood glucose 204\u003c\/p\u003e \u003cp\u003eMonitoring diabetes 205\u003c\/p\u003e \u003cp\u003eMeasuring blood glucose 206\u003c\/p\u003e \u003cp\u003eMeasuring ketones 207\u003c\/p\u003e \u003cp\u003eDrug use in diabetes 207\u003c\/p\u003e \u003cp\u003eInsulin replacement therapy 207\u003c\/p\u003e \u003cp\u003eMetformin 209\u003c\/p\u003e \u003cp\u003eSulfonylureas 209\u003c\/p\u003e \u003cp\u003eIncretin mimetics 210\u003c\/p\u003e \u003cp\u003eSGLT-2 inhibitors 210\u003c\/p\u003e \u003cp\u003eThiazolidinediones 211\u003c\/p\u003e \u003cp\u003eAlpha-glucosidase inhibitors 211\u003c\/p\u003e \u003cp\u003eDrug use in diabetic emergencies 211\u003c\/p\u003e \u003cp\u003eHypoglycaemic emergency 211\u003c\/p\u003e \u003cp\u003eHyperglycaemic emergency 216\u003c\/p\u003e \u003cp\u003eManagement of hyperglycaemia 218\u003c\/p\u003e \u003cp\u003eConclusion 219\u003c\/p\u003e \u003cp\u003eGlossary 219\u003c\/p\u003e \u003cp\u003eReferences 220\u003c\/p\u003e \u003cp\u003eMultiple-choice questions 221\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 13: Medications used in the respiratory system 224\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eJason McKenna\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAim 224\u003c\/p\u003e \u003cp\u003eIntroduction 225\u003c\/p\u003e \u003cp\u003eAnatomy and physiology 225\u003c\/p\u003e \u003cp\u003eNervous system control 226\u003c\/p\u003e \u003cp\u003eCommon respiratory emergencies 227\u003c\/p\u003e \u003cp\u003eAsthma 227\u003c\/p\u003e \u003cp\u003eChronic obstructive pulmonary disease 230\u003c\/p\u003e \u003cp\u003eCroup 231\u003c\/p\u003e \u003cp\u003ePneumonia 232\u003c\/p\u003e \u003cp\u003ePneumothorax 232\u003c\/p\u003e \u003cp\u003ePulmonary oedema 233\u003c\/p\u003e \u003cp\u003eClasses of medications 234\u003c\/p\u003e \u003cp\u003eBronchodilators 234\u003c\/p\u003e \u003cp\u003eDiuretics 236\u003c\/p\u003e \u003cp\u003eNitrates 236\u003c\/p\u003e \u003cp\u003eSteroids 237\u003c\/p\u003e \u003cp\u003eMedical gases 238\u003c\/p\u003e \u003cp\u003eOxygen devices 238\u003c\/p\u003e \u003cp\u003eConclusion 239\u003c\/p\u003e \u003cp\u003eFind out more 239\u003c\/p\u003e \u003cp\u003eReferences 239\u003c\/p\u003e \u003cp\u003eFurther reading 241\u003c\/p\u003e \u003cp\u003eMultiple-choice questions 241\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 14: Medications used in the gastrointestinal system 243\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eGeorge Bell-Starr and Ashley Ingram\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAim 243\u003c\/p\u003e \u003cp\u003eIntroduction 244\u003c\/p\u003e \u003cp\u003eAnatomy and physiology of the gastrointestinal system 244\u003c\/p\u003e \u003cp\u003eNausea and vomiting 244\u003c\/p\u003e \u003cp\u003eH1 receptor antagonists (antihistamines) 246\u003c\/p\u003e \u003cp\u003eDopamine (D2) receptor antagonists 246\u003c\/p\u003e \u003cp\u003eSerotonin (5-HT3) receptor antagonists 246\u003c\/p\u003e \u003cp\u003ePeptic ulcers 247\u003c\/p\u003e \u003cp\u003eHelicobacter pylori infections 247\u003c\/p\u003e \u003cp\u003eNon-steroidal anti-inflammatory drugs 248\u003c\/p\u003e \u003cp\u003eSymptoms of peptic ulcer 248\u003c\/p\u003e \u003cp\u003eConstipation 249\u003c\/p\u003e \u003cp\u003eLaxatives 249\u003c\/p\u003e \u003cp\u003eGastro-oesophageal reflux disease 251\u003c\/p\u003e \u003cp\u003eDrug interventions (patients with confirmed endoscope diagnosis) 252\u003c\/p\u003e \u003cp\u003eParamedic practice 252\u003c\/p\u003e \u003cp\u003eAntidiarrhoeals 254\u003c\/p\u003e \u003cp\u003eInflammatory bowel disease (IBD) 255\u003c\/p\u003e \u003cp\u003eCrohn’s disease 255\u003c\/p\u003e \u003cp\u003eUlcerative colitis 255\u003c\/p\u003e \u003cp\u003eDrug treatment for inflammatory bowel disease 255\u003c\/p\u003e \u003cp\u003eConclusion 257\u003c\/p\u003e \u003cp\u003eReferences 257\u003c\/p\u003e \u003cp\u003eMultiple-choice questions 258\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 15: Medication and the nervous system 261\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eGeoffrey Bench, Alastair Dolan, Lena Solanki, Paul Doherty, Charlotte White, Ricky Lawrence and\u003c\/i\u003e \u003ci\u003eEmma Beadle\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAim 261\u003c\/p\u003e \u003cp\u003eIntroduction 261\u003c\/p\u003e \u003cp\u003eThe nervous system 262\u003c\/p\u003e \u003cp\u003eParkinson disease and parkinsonism 262\u003c\/p\u003e \u003cp\u003eInfections 264\u003c\/p\u003e \u003cp\u003eDementia 264\u003c\/p\u003e \u003cp\u003eDrugs used in dementia 265\u003c\/p\u003e \u003cp\u003eCautions 266\u003c\/p\u003e \u003cp\u003eEpilepsy 267\u003c\/p\u003e \u003cp\u003eAntiepileptic medication 268\u003c\/p\u003e \u003cp\u003ePsychogenic non-epileptic seizures (PNES) versus bilateral tonic clonic seizures (BTCS) 268\u003c\/p\u003e \u003cp\u003eEmergency medication in the prehospital setting 268\u003c\/p\u003e \u003cp\u003eStrokes (including transient ischaemic attacks) 270\u003c\/p\u003e \u003cp\u003eDefinition of a stroke and a transient ischaemic attack 271\u003c\/p\u003e \u003cp\u003eAssessment of a stroke 271\u003c\/p\u003e \u003cp\u003eTreatment 272\u003c\/p\u003e \u003cp\u003eConclusion 274\u003c\/p\u003e \u003cp\u003eReferences 274\u003c\/p\u003e \u003cp\u003eFurther reading\/resources 275\u003c\/p\u003e \u003cp\u003eMultiple-choice questions 276\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 16: Medications used in mental health 278\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eLiam Rooney\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAim 278\u003c\/p\u003e \u003cp\u003eIntroduction 278\u003c\/p\u003e \u003cp\u003eNeurotransmitters 279\u003c\/p\u003e \u003cp\u003eAntidepressants 280\u003c\/p\u003e \u003cp\u003eSelective serotonin reuptake inhibitors 281\u003c\/p\u003e \u003cp\u003eMonoamine oxidase inhibitors 282\u003c\/p\u003e \u003cp\u003eSerotonin and noradrenaline reuptake inhibitors 283\u003c\/p\u003e \u003cp\u003eSerotonin syndrome 283\u003c\/p\u003e \u003cp\u003eOther atypical antidepressants 284\u003c\/p\u003e \u003cp\u003eAnxiolytics 285\u003c\/p\u003e \u003cp\u003ePregabalin 285\u003c\/p\u003e \u003cp\u003eBenzodiazepines 285\u003c\/p\u003e \u003cp\u003eBuspirone 286\u003c\/p\u003e \u003cp\u003eBeta-blockers 286\u003c\/p\u003e \u003cp\u003eHypnotics 286\u003c\/p\u003e \u003cp\u003eBenzodiazepines 286\u003c\/p\u003e \u003cp\u003eZ-drugs 287\u003c\/p\u003e \u003cp\u003eMood-stabilising medications 287\u003c\/p\u003e \u003cp\u003eLithium 287\u003c\/p\u003e \u003cp\u003eValproate 287\u003c\/p\u003e \u003cp\u003eAntipsychotics 288\u003c\/p\u003e \u003cp\u003eAntipsychotic-related side-effects 288\u003c\/p\u003e \u003cp\u003eOther side-effects 289\u003c\/p\u003e \u003cp\u003eDementia 291\u003c\/p\u003e \u003cp\u003eAcetylcholinesterase inhibitors 291\u003c\/p\u003e \u003cp\u003eMemantine 292\u003c\/p\u003e \u003cp\u003eAttention deficit-hyperactivity disorder 292\u003c\/p\u003e \u003cp\u003eStimulants 292\u003c\/p\u003e \u003cp\u003eNon-stimulants 292\u003c\/p\u003e \u003cp\u003eConclusion 293\u003c\/p\u003e \u003cp\u003eFind out more about these conditions 293\u003c\/p\u003e \u003cp\u003eGlossary 293\u003c\/p\u003e \u003cp\u003eReferences 294\u003c\/p\u003e \u003cp\u003eFurther reading 296\u003c\/p\u003e \u003cp\u003eResources 296\u003c\/p\u003e \u003cp\u003eMultiple-choice questions 296\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 17: Immunisations 299\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eMichael Fanner\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAim 299\u003c\/p\u003e \u003cp\u003eIntroduction 299\u003c\/p\u003e \u003cp\u003eUnderstanding the fundamental epidemiological concepts and theories in preventing infectious diseases 300\u003c\/p\u003e \u003cp\u003eEssential ways of examining infectious diseases 301\u003c\/p\u003e \u003cp\u003eBecoming familiar with vaccine design to underpin clinical practice knowledge 302\u003c\/p\u003e \u003cp\u003eVaccine design 302\u003c\/p\u003e \u003cp\u003eAppreciating public concerns in the acceptability and uptake of immunisations 303\u003c\/p\u003e \u003cp\u003eVaccine acceptability 307\u003c\/p\u003e \u003cp\u003eRecognising the role of the paramedic in health promotion and immunisation administration 308\u003c\/p\u003e \u003cp\u003eImmunisations as prescription-only medicines 308\u003c\/p\u003e \u003cp\u003eEmbedding immunisation history taking in clinical assessment 309\u003c\/p\u003e \u003cp\u003eConclusion 315\u003c\/p\u003e \u003cp\u003eReferences 316\u003c\/p\u003e \u003cp\u003eFurther reading 317\u003c\/p\u003e \u003cp\u003eMultiple-choice questions 317\u003c\/p\u003e \u003cp\u003eNormal Values 319\u003c\/p\u003e \u003cp\u003eAnswers 323\u003c\/p\u003e \u003cp\u003eIndex 325\u003c\/p\u003e \u003cp\u003e\u003cb\u003eIan Peate, OBE, FRCN,\u003c\/b\u003e Senior Lecturer, Roehampton University; Visiting Professor of Nursing, St George’s University of London and Kingston University London; Visiting Professor, Northumbria University; Visiting Senior Clinical Fellow, University of Hertfordshire, and Editor-in-Chief of the \u003ci\u003eBritish Journal of Nursing. \u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e Suzanne Evans, PhD\u003c\/b\u003e is Associate Professor and Director of Teaching \u0026amp; Learning, School of Biomedical Sciences \u0026amp; Pharmacy, University of Newcastle, Australia.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eLisa Clegg, PhD, MHLTHSC, BHLTHSC\u003c\/b\u003e is an Ahpra Registered Paramedic and Senior Lecturer in Paramedicine at Charles Sturt University, Australia.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eFundamentals of Pharmacology\u003c\/b\u003e for Paramedics\u003c\/p\u003e \u003cp\u003e\u003ci\u003eFundamentals of Pharmacology for Paramedics\u003c\/i\u003e provides students with the insight and understanding of pharmacological essentials needed to respond effectively to the patient’s needs. This textbook will help students improve, expand, and enhance their expertise and the overall health and wellbeing of their patients, while boosting their self-confidence as paramedics in the process. The book integrates the extensive knowledge of pharmacology required into a workable and accessible plan of care that will help to improve patient care.  \u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eThorough introduction to pharmacology and how to use pharmaceutical and prescribing reference guides\u003c\/li\u003e \u003cli\u003eComprehensive exploration of the legal and ethical issues of pharmacology within paramedicine and the role of the paramedic in medicines management\u003c\/li\u003e \u003cli\u003ePractical discussion of pharmacodynamics, pharmacokinetics, drug formulations, and adverse drug reactions\u003c\/li\u003e \u003cli\u003eIn-depth examinations of a wide variety of medicines, including analgesics, antibacterials, and medications used in the cardiovascular, renal, respiratory, gastrointestinal, and nervous systems\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003eWritten for students of paramedicine, \u003ci\u003eFundamentals of Pharmacology for Paramedics\u003c\/i\u003e would also prove an indispensable resource for practicing paramedics seeking a practical, one-stop reference on a challenging subject. \u003c\/p\u003e\u003cp\u003e\u003cb\u003eAll content reviewed by students for students.\u003c\/b\u003e \u003c\/p\u003e\u003cp\u003eIf you would like to be one of our student reviewers, go to \u003cb\u003ewww.reviewnursingbooks.com\u003c\/b\u003e to find out more. \u003c\/p\u003e\u003cp\u003eTo receive automatic updates on Wiley books and journals, join our email list. Sign up today at \u003cb\u003ewww.wiley.com\/email\u003c\/b\u003e\u003c\/p\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47989262385381,"sku":"NP9781119724285","price":38.5,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781119724285.jpg?v=1761783426","url":"https:\/\/k12savings.com\/es\/products\/fundamentals-of-pharmacology-for-paramedics-isbn-9781119724285","provider":"K12savings","version":"1.0","type":"link"}